Evidence map›Paper›PMID 38448539›Full record

ArticleScientific reports2024

Novel biosensor for high-throughput detection of progesterone receptor-interacting endocrine disruptors.

Diana A Stavreva, Lyuba Varticovski, Razi Raziuddin, Gianluca Pegoraro, R Louis Schiltz, Gordon L Hager

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Diana A StavrevaLaboratory of Receptor Biology and Gene Expression, National Cancer Institute, NIH, 41 Medlars Dr., Bethesda, MD, 20892-5055, USA. stavrevd@mail.nih.gov.
Lyuba VarticovskiLaboratory of Receptor Biology and Gene Expression, National Cancer Institute, NIH, 41 Medlars Dr., Bethesda, MD, 20892-5055, USA.
Razi RaziuddinLaboratory of Receptor Biology and Gene Expression, National Cancer Institute, NIH, 41 Medlars Dr., Bethesda, MD, 20892-5055, USA.
Gianluca PegoraroLaboratory of Receptor Biology and Gene Expression, National Cancer Institute, NIH, 41 Medlars Dr., Bethesda, MD, 20892-5055, USA.
R Louis SchiltzLaboratory of Receptor Biology and Gene Expression, National Cancer Institute, NIH, 41 Medlars Dr., Bethesda, MD, 20892-5055, USA.
Gordon L HagerLaboratory of Receptor Biology and Gene Expression, National Cancer Institute, NIH, 41 Medlars Dr., Bethesda, MD, 20892-5055, USA. hagerg@exchange.nih.gov.
National Institutes of Health · USNational Cancer Institute · US

Funding

HiTIF Microscopy Core FacilityZICBC011567 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PEGORARO, GIANLUCA · 2014 to 2025
$15.8M
In vivo Imaging Analysis of SteroidNuclear Receptor FunctionZIABC010308 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HAGER, GORDON L · 2009 to 2025
$8.4M
6 · The paper itself

Abstract

Progesterone receptor (PR)-interacting compounds in the environment are associated with serious health hazards. However, methods for their detection in environmental samples are cumbersome. We report a sensitive activity-based biosensor for rapid and reliable screening of progesterone receptor (PR)-interacting endocrine disrupting chemicals (EDCs). The biosensor is a cell line which expresses nuclear mCherry-NF1 and a green fluorescent protein (GFP)-tagged chimera of glucocorticoid receptor (GR) N terminus fused to the ligand binding domain (LBD) of PR (GFP-GR-PR). As this LBD is shared by the PRA and PRB, the biosensor reports on the activation of both PR isoforms. This GFP-GR-PR chimera is cytoplasmic in the absence of hormone and translocates rapidly to the nucleus in response to PR agonists or antagonists in concentration- and time-dependent manner. In live cells, presence of nuclear NF1 label eliminates cell fixation and nuclear staining resulting in efficient screening. The assay can be used in screens for novel PR ligands and PR-interacting contaminants in environmental samples. A limited screen of river water samples indicated a widespread, low-level contamination with PR-interacting contaminants in all tested samples.

Indexed as

Endocrine DisruptorsBiological AssayCell LineCytoplasmGreen Fluorescent ProteinsReceptors, GlucocorticoidReceptors, ProgesteroneEndocrine DisruptorsGreen Fluorescent ProteinsReceptors, GlucocorticoidReceptors, ProgesteroneBiological activityHormonesRiver waterScreening

Identifiers

PMID38448539
PMCPMC10917811
OpenAlexW4392520376

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.